focus -WSS

focus

author：explore 2025-10-02 22:58:35 - browse：2951

Adobe

The Food and Drug Administration is expected to approve Merck’s drug to treat a rare lung disorder called pulmonary arterial hypertension on Tuesday, making available a novel treatment for a deadly condition that’s long been challenging to treat.

In a large trial published last year, the drug, called sotatercept, exceeded expectations in significantly increasing the distance that patients could walk and cutting the risk that their condition would worsen, that they would die, and that they would need new treatments.

Pulmonary arterial hypertension, or PAH, is estimated to occur in 15 to 50 per million people, mostly in women. It’s characterized by a proliferation of cells in the blood vessels that connect the right side of heart to the lungs, making it harder for blood to pass through and leading the heart to have to work harder to pump blood into the lungs. The disease, which causes difficulty breathing, fatigue and dizziness, has a high mortality rate, with one study finding that one-fifth of patients died at around three years after diagnosis.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Drug repurposing or repositioning? The language matters
Next article： Radiation, mainstay of cancer treatment, begins a fade

focus

WSS

What AAP's gender

H5N1 communication has been strictly for the birds

CDC wastewater surveillance dashboard to track bird flu hotspots

How to improve immunocompromised access to mAb treatments

Radiation, mainstay of cancer treatment, begins a fade

H5N1 communication has been strictly for the birds

Wikipedia

focus

hotspot

Bright Health sells Medicare Advantage business to Molina

Steward Health Care files for bankruptcy

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Steward Health Care files for bankruptcy

BioMarin wins approval for gene therapy to treat hemophilia A

Neuroscience startup Neumora files for IPO

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Brain worms: The science behind RFK Jr.'s parasitic infection

Medicare details structure of new drug price negotiation program

FDA panel gives mixed vote on blood pressure devices

focus

Shionogi licenses Pompe disease therapy from Maze Therapeutics

Steward Health Care files for bankruptcy

Medicare says breakthrough device reimbursement rule to come by summer

H5N1 bird flu: what we're starting to learn about infection in cows

Study: AI not yet building 'n

Medicare says breakthrough device reimbursement rule to come by summer

entertainment

focus

focus

focus